Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19.

Foo, Hong; Phan, Fiona; Bagatella, Melissa; Petrovski, Irene; Nagendra, Vana; Acharya, Priya; Levy, Miriam; Prakoso, Emilia

Foo, Hong; Phan, Fiona; Bagatella, Melissa; Petrovski, Irene; Nagendra, Vana; Acharya, Priya; Levy, Miriam; Prakoso, Emilia.

Afiliación

Foo H; Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia. hong.foo@health.nsw.gov.au.
Phan F; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
Bagatella M; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
Petrovski I; Department of Gastroenterology, Campbelltown Hospital, Sydney, Australia.
Nagendra V; Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia.
Acharya P; Department of Gastroenterology, Campbelltown Hospital, Sydney, Australia.
Levy M; Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
Prakoso E; University of New South Wales, Sydney, Australia.

Eur J Clin Microbiol Infect Dis ; 42(6): 799-801, 2023 06.

Article en En | MEDLINE | ID: mdl-37084117

Asunto(s)

COVID-19; Hepatitis B; Humanos; Tratamiento Farmacológico de COVID-19; Virus de la Hepatitis B

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Hepatitis B Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Clin Microbiol Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google